BBOT BridgeBio Oncology Therapeutics
$2.85▲ +5.95%
Healthcare
Other
Volume 256.3K
Avg Volume (10D) 733.2K
Key Metrics & Fundamentals
Market Cap
$228.50M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.51 - 14.87
% vs 50 MA
-50.10%
% vs 200 MA
-67.49%
RSI-14
21.9
MACD Histogram
+0.1100
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$44.41M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$60.00M
COGS
–
Operating Exp
$60.19M
Operating Income
-$60.19M
EBIT
-$60.19M
Pretax Income
-$56.45M
Net Income
-$56.45M
EPS (Diluted)
-705.20
Price & Volume History
Loading chart…
Recent News
Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16 From $22, Maintains Outperform Rating
MT Newswires · Oct 20, 2026 9:12 AM ET
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 12, 2026 4:05 PM ET
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
Insider Monkey · Sep 12, 2026 3:40 AM ET
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · Sep 11, 2026 5:37 AM ET
BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results
MT Newswires · Sep 8, 2026 5:29 PM ET
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
GlobeNewswire · Sep 8, 2026 4:05 PM ET
BBOT to Participate in Upcoming Investor Healthcare Conferences
GlobeNewswire · Sep 1, 2026 4:05 PM ET
BridgeBio Oncology Q2 Loss Widens
MT Newswires · Aug 11, 2026 5:13 PM ET
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 11, 2026 4:40 PM ET
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
GlobeNewswire · Aug 11, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BBOT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.